Angenommen, einer Person/Institution gelingt die Zulassung einer Therapie zur Heilung der Parkinsonschen Krankheit – vor Ende 2030.
Wären Sie bereit, dieser Person/Institution eine Belohnung in Höhe von 1.000 € zu bezahlen? Das entspricht in etwa den Medikamentenkosten für einen Patienten pro Monat.
Sollten Sie dazu bereit sein und nehmen wir an, auch die übrigen ca. eine Million Patienten Europas wären dazu bereit, ergäbe sich eine Summe in Höhe von ca. einer Milliarde EURO. Dieses Geld wird nur im Erfolgsfalle fällig.
Eine solche „Erfolgsprämie“ sollte einen spürbaren Motivationsschub für die Parkinson-Forschung und Therapie-Entwicklung mit sich bringen – insbesondere, weil dieses Geld direkt von den Patienten und Betroffenen kommt.
Wären Sie prinzipiell dabei?
Die Teilnahme an der Umfrage führt zu keinen Verpflichtungen, insbesondere zu keinen Zahlungsverpflichtungen.
Imagine, a person / institution succeeds in obtaining approval for a therapy to cure Parkinson’s disease – before the end of 2030. Would you be willing to pay this person / institution a reward of € 1,000? This roughly corresponds to the drug costs for one patient per month. If you are ready and we assume that the remaining approximately one million patients in Europe would also be ready, this would result in a sum of approximately one billion euros. This money is only due in case of success. Such a “success bonus” should bring a noticeable boost in motivation for Parkinson’s research and therapy development – especially because this money comes directly from the patients and those affected. Would you be there in principle? Participation in the survey does not lead to any obligations, in particular no payment obligations.
Considerations that led to the survey
Are you by chance already a Parkinson’s patient and therefore part of one of the fastest growing patient communities in Europe? We now have more than a million increasingly younger diagnosed patients and several million who are directly affected as partners, relatives, friends or employers. We believe it is time to take our fate into our own hands again, so that together we can end the element that unites us, the livelihood of our community – to eliminate Parkinson’s. Only if we patients become the driving force in the fight against this insidious disease and fight with all our (remaining) strength – do we have a chance to experience that Parkinson’s is curable. There are some indications that no one else has an interest in defeating this disease (see below „Two quotes“). The availability of IQ and € determines the success of the mission and its duration. Both condition each other and attract each other. By the way, according to a recent scientific study (Smarter then the average Björn), Parkinson’s patients are on average above average intelligent. In addition, they or society can afford to consume medication for an average of more than € 1,000 – month after month, often for decades. We should use these circumstances to put an end to our suffering.
Two quotes from emails from contributors:
1. “Nobody wants to cure Parkinson’s … The manufacturing industry has, to put it again very clearly, ZERO interest in our desire and desire to overcome Parkinson’s. They live well from it and with the fact that it is not curable! And the service provider right down to the meticulously organized specialist clinics, nursing services, specialist medical practices, etc. are only our friends as long as we dump money there without any alternative. Nothing is more scary economically than a cured patient! … „
2. One of the scientists who support this project wrote recently: “It will certainly not be easy to get large-scale public funding for new Parkinson’s research. Health research as a whole has far too little value in the political priorities for this. So the EU budget under Pillar 2 of the Horizon Europe research program is around 7? Billions in total less than that of all other areas (climate, energy, food … That is particularly astonishing when you consider that the EU spends around 4.5 billion per day on health costs. The concept of saving costs through research obviously still has European politics not convinced. * I see the best chance in a patient-driven project, similar to the Hereditary Disease Foundation, which has definitely accelerated the identification of the HD gene. Sergej Brin / Google, for example, could theoretically contribute more to Parkinson’s research than that in the next few years EU will spend on health research as a whole in its framework program.“